uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
March 21, 2022 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, March 21, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces 2021 Financial Results and Highlights Recent Company Progress
February 25, 2022 07:05 ET
|
uniQure Inc.
~ Data from largest gene therapy study in hemophilia B showed sustained therapeutic effect at 18-months and statistical superiority in reducing annualized bleeding rate compared to baseline FIX...
uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease
February 07, 2022 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Feb. 07, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Clinical Update on First Patients in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
December 16, 2021 07:00 ET
|
uniQure Inc.
~ Treatment was well tolerated with no significant safety issues related to AMT-130 in first two treated patients through one year of follow-up ~ ~ Neurofilament Light Chain (NfL) rose as expected...
uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
December 09, 2021 07:05 ET
|
uniQure Inc.
~ Largest gene therapy study in hemophilia B achieved primary endpoint of non-inferiority in annualized bleeding rate after stable Factor IX (FIX) expression, assessed at 18 months following a single...
uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
November 02, 2021 07:05 ET
|
uniQure Inc.
~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02,...
uniQure to Participate in Upcoming Industry Conferences in November
November 01, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Nov. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
October 25, 2021 07:05 ET
|
uniQure Inc.
~ Completed 78-week follow-up for hemophilia B pivotal study, with top-line data expected by year-end 2021 ~ ~ Enrolled 14 patients to date in Phase 1/2 clinical trial of AMT-130 in Huntington’s...
uniQure Announces the Appointment of Rachelle Jacques to its Board of Directors
October 21, 2021 09:30 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 21, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Presentations at the Annual Meeting of The European Society of Gene and Cell Therapy (ESGCT)
October 19, 2021 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Oct. 19, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...